Zacks Investment Research on MSN3h
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...
Defense Platforms and Systems Outlook Industry worth $2,460.0 billion in 2024 - Exclusive Report by MarketsandMarkets™
The report "Defense Platforms and Systems Outlook 2025: Emerging Technologies, Evolving Disruptions, Outlook and Growth Opportunities" ...
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in ...
Le Lézard7h
CardioVia Announces FDA Clearance for ViaOne, Opening a New Frontier in Minimally Invasive Heart-Surface Treatments
CardioVia, an innovative medical device company specializing in advanced cardiac care solutions, announced today that it has received U.S. Food and Drug Administration (FDA) clearance for its ViaOne ...
Le Lézard7h
Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOLtm PF for the Treatment of Presbyopia
Tenpoint Therapeutics, Ltd. ("Tenpoint"), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the ...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...
Rein Therapeutics, Inc.: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the ...
Rein Therapeutics Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business Update
Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary f ...